Natera (NASDAQ:NTRA) Price Target Raised to $32.00 at Piper Jaffray Companies

Natera (NASDAQ:NTRA) had its price objective raised by Piper Jaffray Companies from $28.00 to $32.00 in a research note published on Thursday morning, The Fly reports. The firm currently has an overweight rating on the medical research company’s stock.

Other research analysts have also issued reports about the stock. BidaskClub upgraded shares of Natera from a sell rating to a hold rating in a report on Wednesday, June 12th. Zacks Investment Research lowered shares of Natera from a hold rating to a sell rating in a report on Wednesday, July 17th. Finally, Canaccord Genuity increased their price objective on shares of Natera from $32.00 to $36.00 and gave the stock a buy rating in a report on Thursday. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus target price of $32.29.

Shares of NTRA stock traded up $0.49 during trading hours on Thursday, hitting $32.38. 1,231,052 shares of the company were exchanged, compared to its average volume of 615,463. The stock has a market cap of $2.22 billion, a price-to-earnings ratio of -15.06 and a beta of 1.51. Natera has a 1 year low of $11.08 and a 1 year high of $33.25. The company has a debt-to-equity ratio of 20.88, a quick ratio of 1.73 and a current ratio of 1.85. The business’s fifty day moving average price is $26.66.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Wednesday, August 7th. The medical research company reported ($0.48) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.57) by $0.09. The business had revenue of $74.36 million for the quarter, compared to analyst estimates of $66.77 million. Natera had a negative net margin of 46.78% and a negative return on equity of 409.49%. The company’s revenue was up 17.9% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.62) EPS. As a group, equities research analysts predict that Natera will post -2.1 earnings per share for the current year.

In related news, insider Jonathan Sheena sold 1,033 shares of the stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $24.79, for a total transaction of $25,608.07. Following the completion of the sale, the insider now owns 240,061 shares of the company’s stock, valued at approximately $5,951,112.19. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Chairman Matthew Rabinowitz sold 1,418 shares of the stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $24.79, for a total transaction of $35,152.22. Following the sale, the chairman now directly owns 1,286,612 shares of the company’s stock, valued at approximately $31,895,111.48. The disclosure for this sale can be found here. In the last three months, insiders have sold 5,311 shares of company stock valued at $132,287. Corporate insiders own 9.29% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Perkins Capital Management Inc. increased its position in Natera by 121.3% during the 1st quarter. Perkins Capital Management Inc. now owns 129,900 shares of the medical research company’s stock worth $2,679,000 after purchasing an additional 71,200 shares in the last quarter. Principal Financial Group Inc. increased its position in Natera by 60.3% during the 4th quarter. Principal Financial Group Inc. now owns 233,205 shares of the medical research company’s stock worth $3,255,000 after purchasing an additional 87,750 shares in the last quarter. FMR LLC increased its position in Natera by 57.0% during the 4th quarter. FMR LLC now owns 3,908,921 shares of the medical research company’s stock worth $54,568,000 after purchasing an additional 1,419,390 shares in the last quarter. Geode Capital Management LLC increased its position in Natera by 6.1% during the 4th quarter. Geode Capital Management LLC now owns 463,029 shares of the medical research company’s stock worth $6,463,000 after purchasing an additional 26,771 shares in the last quarter. Finally, Kornitzer Capital Management Inc. KS increased its position in Natera by 64.2% during the 1st quarter. Kornitzer Capital Management Inc. KS now owns 513,141 shares of the medical research company’s stock worth $10,581,000 after purchasing an additional 200,550 shares in the last quarter. 80.12% of the stock is owned by hedge funds and other institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Read More: Balanced Fund

The Fly

Analyst Recommendations for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.